Target Gene/Pathway Pathway / Gene


Search results


No. KEGG PATHWAY
On map, Yellow: Drug target, Red: All disease-related
KEGG GENES KEGG DRUG DrugBank 指定難病告示番号
1 Acute myeloid leukemia 💬
1件: RARA 💬 Isotretinoin 💬 Isotretinoin 4件: 36, 39, 159, 160 💬
2 Adherens junction 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
3 Adherens junction 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
4 Adipocytokine signaling pathway 💬
1件: NR1C1 💬 Bezafibrate 💬 Bezafibrate 8件: 20, 93, 94, 160, 296, 316, 324, 344 💬
5 Adipocytokine signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
6 African trypanosomiasis 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
7 African trypanosomiasis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
8 AGE-RAGE signaling pathway in diabetic complications 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
9 Alcoholic liver disease 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
10 Alcoholic liver disease 💬
1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
11 Alcoholic liver disease 💬
1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
12 Alcoholic liver disease 💬
1件: NR1C1 💬 Bezafibrate 💬 Bezafibrate 8件: 20, 93, 94, 160, 296, 316, 324, 344 💬
13 Alcoholic liver disease 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
14 Allograft rejection 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
15 Allograft rejection 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
16 Allograft rejection 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
17 Alzheimer disease 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
18 Alzheimer disease 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
19 Amoebiasis 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
20 Amoebiasis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
21 Amphetamine addiction 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
22 AMPK signaling pathway 💬
1件: HMGCR 💬 Atorvastatin calcium 💬 Atorvastatin 20件: 13, 22, 46, 49, 51, 58, 63, 67, 79, 84, 88, 93, 96, 97, 160, 225, 265, 271, 297, 299 💬
23 AMPK signaling pathway 💬
1件: HMGCR 💬 Atorvastatin 💬 Atorvastatin 20件: 13, 22, 46, 49, 51, 58, 63, 67, 79, 84, 88, 93, 96, 97, 160, 225, 265, 271, 297, 299 💬
24 AMPK signaling pathway 💬
1件: HMGCR 💬 Lovastatin 💬 Lovastatin 11件:  6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬
25 AMPK signaling pathway 💬
1件: HMGCR 💬 Simvastatin 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
26 Amyotrophic lateral sclerosis 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
27 Amyotrophic lateral sclerosis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
28 Antigen processing and presentation 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
29 Apoptosis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
30 Arachidonic acid metabolism 💬
1件: ALOX5 💬 Zileuton 💬 Zileuton 3件: 85, 160, 164 💬
31 Asthma 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
32 Autoimmune thyroid disease 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
33 Axon guidance 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
34 B cell receptor signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
35 Bile secretion 💬
1件: HMGCR 💬 Atorvastatin calcium 💬 Atorvastatin 20件: 13, 22, 46, 49, 51, 58, 63, 67, 79, 84, 88, 93, 96, 97, 160, 225, 265, 271, 297, 299 💬
36 Bile secretion 💬
1件: HMGCR 💬 Atorvastatin 💬 Atorvastatin 20件: 13, 22, 46, 49, 51, 58, 63, 67, 79, 84, 88, 93, 96, 97, 160, 225, 265, 271, 297, 299 💬
37 Bile secretion 💬
1件: HMGCR 💬 Lovastatin 💬 Lovastatin 11件:  6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬
38 Bile secretion 💬
1件: HMGCR 💬 Simvastatin 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
39 Bladder cancer 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
40 Bladder cancer 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
41 Breast cancer 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
42 Breast cancer 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
43 C-type lectin receptor signaling pathway 💬
3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
44 C-type lectin receptor signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
45 C-type lectin receptor signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
46 Calcium signaling pathway 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
47 Calcium signaling pathway 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
48 Calcium signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
49 cAMP signaling pathway 💬
1件: NR1C1 💬 Bezafibrate 💬 Bezafibrate 8件: 20, 93, 94, 160, 296, 316, 324, 344 💬
50 Cell adhesion molecules 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
51 Cellular senescence 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
52 Central carbon metabolism in cancer 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
53 Central carbon metabolism in cancer 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
54 cGMP-PKG signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
55 Chagas disease 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
56 Chagas disease 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
57 Chemical carcinogenesis - reactive oxygen species 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
58 Chemical carcinogenesis - reactive oxygen species 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
59 Chemical carcinogenesis - receptor activation 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
60 Chemical carcinogenesis - receptor activation 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
61 Chemical carcinogenesis - receptor activation 💬
1件: NR1C1 💬 Bezafibrate 💬 Bezafibrate 8件: 20, 93, 94, 160, 296, 316, 324, 344 💬
62 Choline metabolism in cancer 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
63 Choline metabolism in cancer 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
64 Colorectal cancer 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
65 Colorectal cancer 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
66 Coronavirus disease - COVID-19 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
67 Coronavirus disease - COVID-19 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
68 Coronavirus disease - COVID-19 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
69 Coronavirus disease - COVID-19 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
70 Coronavirus disease - COVID-19 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
71 Cushing syndrome 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
72 Cushing syndrome 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
73 Cytokine-cytokine receptor interaction 💬
3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
74 Cytokine-cytokine receptor interaction 💬
1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
75 Cytokine-cytokine receptor interaction 💬
1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
76 Cytokine-cytokine receptor interaction 💬
1件: IL1RL2 💬 Spesolimab 💬 Spesolimab 5件: 37, 96, 97, 160, 269 💬
77 Cytokine-cytokine receptor interaction 💬
1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
78 Cytokine-cytokine receptor interaction 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
79 Diabetic cardiomyopathy 💬
1件: NR1C1 💬 Bezafibrate 💬 Bezafibrate 8件: 20, 93, 94, 160, 296, 316, 324, 344 💬
80 Dilated cardiomyopathy 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
81 Dopaminergic synapse 💬
3件: PPP3C, PPP3C, PPP3C 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
82 Efferocytosis 💬
1件: ALOX5 💬 Zileuton 💬 Zileuton 3件: 85, 160, 164 💬
83 Endocytosis 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
84 Endocytosis 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
85 Endometrial cancer 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
86 Endometrial cancer 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
87 Epithelial cell signaling in Helicobacter pylori infection 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
88 Epithelial cell signaling in Helicobacter pylori infection 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
89 Epstein-Barr virus infection 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
90 Epstein-Barr virus infection 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
91 ErbB signaling pathway 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
92 ErbB signaling pathway 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
93 Estrogen signaling pathway 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
94 Estrogen signaling pathway 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
95 Estrogen signaling pathway 💬
1件: RARA 💬 Isotretinoin 💬 Isotretinoin 4件: 36, 39, 159, 160 💬
96 Fc epsilon RI signaling pathway 💬
1件: ALOX5 💬 Zileuton 💬 Zileuton 3件: 85, 160, 164 💬
97 Fc epsilon RI signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
98 Fluid shear stress and atherosclerosis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
99 Focal adhesion 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
100 Focal adhesion 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
101 FoxO signaling pathway 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
102 FoxO signaling pathway 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
103 Gap junction 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
104 Gap junction 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
105 Gastric cancer 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
106 Gastric cancer 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
107 Gastric cancer 💬
1件: RARB 💬 Isotretinoin 💬 Isotretinoin 4件: 36, 39, 159, 160 💬
108 Glioma 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
109 Glioma 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
110 Glucagon signaling pathway 💬
1件: NR1C1 💬 Bezafibrate 💬 Bezafibrate 8件: 20, 93, 94, 160, 296, 316, 324, 344 💬
111 Glucagon signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
112 Glutamatergic synapse 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
113 GnRH signaling pathway 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
114 GnRH signaling pathway 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
115 Graft-versus-host disease 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
116 Graft-versus-host disease 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
117 Hematopoietic cell lineage 💬
1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
118 Hematopoietic cell lineage 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
119 Hepatitis B 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
120 Hepatitis B 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
121 Hepatitis C 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
122 Hepatitis C 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
123 Hepatitis C 💬
1件: NR1C1 💬 Bezafibrate 💬 Bezafibrate 8件: 20, 93, 94, 160, 296, 316, 324, 344 💬
124 Hepatitis C 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
125 Hepatitis C 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
126 Hepatocellular carcinoma 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
127 Hepatocellular carcinoma 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
128 Herpes simplex virus 1 infection 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
129 Herpes simplex virus 1 infection 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
130 Herpes simplex virus 1 infection 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
131 HIF-1 signaling pathway 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
132 HIF-1 signaling pathway 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
133 Human cytomegalovirus infection 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
134 Human cytomegalovirus infection 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
135 Human cytomegalovirus infection 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
136 Human cytomegalovirus infection 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
137 Human immunodeficiency virus 1 infection 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
138 Human immunodeficiency virus 1 infection 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
139 Human papillomavirus infection 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
140 Human papillomavirus infection 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
141 Human papillomavirus infection 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
142 Human papillomavirus infection 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
143 Human T-cell leukemia virus 1 infection 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
144 Human T-cell leukemia virus 1 infection 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
145 Hypertrophic cardiomyopathy 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
146 IL-17 signaling pathway 💬
1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
147 IL-17 signaling pathway 💬
1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
148 IL-17 signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
149 Inflammatory bowel disease 💬
3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
150 Inflammatory bowel disease 💬
1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
151 Inflammatory bowel disease 💬
1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
152 Inflammatory bowel disease 💬
1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
153 Inflammatory bowel disease 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
154 Influenza A 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
155 Influenza A 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
156 Influenza A 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
157 Insulin resistance 💬
1件: NR1C1 💬 Bezafibrate 💬 Bezafibrate 8件: 20, 93, 94, 160, 296, 316, 324, 344 💬
158 Insulin resistance 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
159 Intestinal immune network for IgA production 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
160 JAK-STAT signaling pathway 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
161 JAK-STAT signaling pathway 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
162 JAK-STAT signaling pathway 💬
3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
163 JAK-STAT signaling pathway 💬
1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
164 JAK-STAT signaling pathway 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
165 Kaposi sarcoma-associated herpesvirus infection 💬
1件: CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
166 Kaposi sarcoma-associated herpesvirus infection 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
167 Kaposi sarcoma-associated herpesvirus infection 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
168 Legionellosis 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
169 Legionellosis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
170 Leishmaniasis 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
171 Leishmaniasis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
172 Lipid and atherosclerosis 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
173 Lipid and atherosclerosis 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
174 Lipid and atherosclerosis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
175 Long-term potentiation 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
176 Malaria 💬
1件: IL12A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
177 Malaria 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
178 MAPK signaling pathway 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
179 MAPK signaling pathway 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
180 MAPK signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
181 MAPK signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
182 Measles 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
183 Measles 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
184 Melanoma 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
185 Melanoma 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
186 MicroRNAs in cancer 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
187 MicroRNAs in cancer 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
188 mTOR signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
189 Natural killer cell mediated cytotoxicity 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
190 Natural killer cell mediated cytotoxicity 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
191 Necroptosis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
192 Necroptosis 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
193 NF-kappa B signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
194 NOD-like receptor signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
195 NOD-like receptor signaling pathway 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
196 Non-alcoholic fatty liver disease 💬
1件: NR1C1 💬 Bezafibrate 💬 Bezafibrate 8件: 20, 93, 94, 160, 296, 316, 324, 344 💬
197 Non-alcoholic fatty liver disease 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
198 Non-small cell lung cancer 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
199 Non-small cell lung cancer 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
200 Non-small cell lung cancer 💬
1件: RARB 💬 Isotretinoin 💬 Isotretinoin 4件: 36, 39, 159, 160 💬
201 Oocyte meiosis 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
202 Osteoclast differentiation 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
203 Osteoclast differentiation 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
204 Osteoclast differentiation 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
205 Ovarian steroidogenesis 💬
1件: ALOX5 💬 Zileuton 💬 Zileuton 3件: 85, 160, 164 💬
206 Oxytocin signaling pathway 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
207 Oxytocin signaling pathway 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
208 Oxytocin signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
209 Pancreatic cancer 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
210 Pancreatic cancer 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
211 Parathyroid hormone synthesis, secretion and action 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
212 Parathyroid hormone synthesis, secretion and action 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
213 Pathogenic Escherichia coli infection 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
214 Pathways in cancer 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
215 Pathways in cancer 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
216 Pathways in cancer 💬
3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
217 Pathways in cancer 💬
1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
218 Pathways in cancer 💬
2件: RARA, RARB 💬 Isotretinoin 💬 Isotretinoin 4件: 36, 39, 159, 160 💬
219 Pathways of neurodegeneration - multiple diseases 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
220 Pathways of neurodegeneration - multiple diseases 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
221 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
222 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
223 PD-L1 expression and PD-1 checkpoint pathway in cancer 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
224 Pertussis 💬
3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
225 Pertussis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
226 Phospholipase D signaling pathway 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
227 Phospholipase D signaling pathway 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
228 PI3K-Akt signaling pathway 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
229 PI3K-Akt signaling pathway 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
230 PI3K-Akt signaling pathway 💬
1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
231 PPAR signaling pathway 💬
1件: NR1C1 💬 Bezafibrate 💬 Bezafibrate 8件: 20, 93, 94, 160, 296, 316, 324, 344 💬
232 Prion disease 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
233 Prion disease 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
234 Prostate cancer 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
235 Prostate cancer 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
236 Proteoglycans in cancer 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
237 Proteoglycans in cancer 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
238 Proteoglycans in cancer 💬
1件: IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
239 Proteoglycans in cancer 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
240 Rap1 signaling pathway 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
241 Rap1 signaling pathway 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
242 Ras signaling pathway 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
243 Ras signaling pathway 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
244 Regulation of actin cytoskeleton 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
245 Regulation of actin cytoskeleton 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
246 Relaxin signaling pathway 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
247 Relaxin signaling pathway 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
248 Renin secretion 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
249 Rheumatoid arthritis 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
250 Rheumatoid arthritis 💬
1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
251 Rheumatoid arthritis 💬
1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
252 Rheumatoid arthritis 💬
1件: IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
253 Rheumatoid arthritis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
254 RIG-I-like receptor signaling pathway 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
255 RIG-I-like receptor signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
256 Salmonella infection 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
257 Serotonergic synapse 💬
1件: ALOX5 💬 Zileuton 💬 Zileuton 3件: 85, 160, 164 💬
258 Shigellosis 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
259 Shigellosis 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
260 Shigellosis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
261 Small cell lung cancer 💬
1件: RARB 💬 Isotretinoin 💬 Isotretinoin 4件: 36, 39, 159, 160 💬
262 Sphingolipid signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
263 Systemic lupus erythematosus 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
264 Systemic lupus erythematosus 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
265 T cell receptor signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
266 T cell receptor signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
267 Terpenoid backbone biosynthesis 💬
1件: HMGCR 💬 Atorvastatin calcium 💬 Atorvastatin 20件: 13, 22, 46, 49, 51, 58, 63, 67, 79, 84, 88, 93, 96, 97, 160, 225, 265, 271, 297, 299 💬
268 Terpenoid backbone biosynthesis 💬
1件: HMGCR 💬 Atorvastatin 💬 Atorvastatin 20件: 13, 22, 46, 49, 51, 58, 63, 67, 79, 84, 88, 93, 96, 97, 160, 225, 265, 271, 297, 299 💬
269 Terpenoid backbone biosynthesis 💬
1件: HMGCR 💬 Lovastatin 💬 Lovastatin 11件:  6 , 34, 46, 79, 156, 160, 195, 206, 263, 280, 310 💬
270 Terpenoid backbone biosynthesis 💬
1件: HMGCR 💬 Simvastatin 💬 Simvastatin 21件:  6 , 13, 15, 34, 46, 49, 51, 66, 79, 86, 89, 94, 158, 160, 162, 195, 265, 288, 298, 299, 310 💬
271 TGF-beta signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
272 Th1 and Th2 cell differentiation 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
273 Th1 and Th2 cell differentiation 💬
1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
274 Th1 and Th2 cell differentiation 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
275 Th1 and Th2 cell differentiation 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
276 Th17 cell differentiation 💬
1件: IL17A 💬 Ixekizumab 💬 Ixekizumab 8件: 36, 37, 46, 107, 160, 162, 269, 271 💬
277 Th17 cell differentiation 💬
1件: IL17A 💬 Secukinumab 💬 Secukinumab 8件: 13, 37, 41, 46, 107, 160, 269, 271 💬
278 Th17 cell differentiation 💬
1件: IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
279 Th17 cell differentiation 💬
1件: IL4R 💬 Dupilumab 💬 Dupilumab 5件: 51, 97, 98, 160, 162 💬
280 Th17 cell differentiation 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
281 Th17 cell differentiation 💬
1件: RARA 💬 Isotretinoin 💬 Isotretinoin 4件: 36, 39, 159, 160 💬
282 Th17 cell differentiation 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
283 TNF signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
284 Toll-like receptor signaling pathway 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
285 Toll-like receptor signaling pathway 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
286 Toll-like receptor signaling pathway 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
287 Toll-like receptor signaling pathway 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
288 Toxoplasmosis 💬
1件: ALOX5 💬 Zileuton 💬 Zileuton 3件: 85, 160, 164 💬
289 Toxoplasmosis 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
290 Toxoplasmosis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
291 Toxoplasmosis 💬
1件: TYK2 💬 Deucravacitinib 💬 Deucravacitinib 9件: 36, 37, 49, 53, 84, 96, 97, 160, 269 💬
292 Transcriptional misregulation in cancer 💬
1件: CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
293 Transcriptional misregulation in cancer 💬
1件: RARA 💬 Isotretinoin 💬 Isotretinoin 4件: 36, 39, 159, 160 💬
294 Tuberculosis 💬
3件: IL12A, IL12B, IL23A 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
295 Tuberculosis 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
296 Tuberculosis 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
297 Type I diabetes mellitus 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
298 Type I diabetes mellitus 💬
2件: IL12A, IL12B 💬 Ustekinumab 💬 Ustekinumab 17件: 37, 40, 41, 46, 49, 50, 53, 56, 65, 84, 93, 96, 97, 160, 162, 269, 271 💬
299 Type I diabetes mellitus 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
300 Type II diabetes mellitus 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
301 VEGF signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
302 Viral myocarditis 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
303 Viral protein interaction with cytokine and cytokine receptor 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬
304 Virion - Adenovirus 💬
2件: CD80, CD86 💬 Abatacept 💬 Abatacept 27件:  2 , 11, 13, 19, 41, 44, 46, 49, 50, 51, 53, 55, 60, 65, 84, 93, 95, 96, 97, 107, 160, 164, 222, 271, 284, 285, 300 💬
305 Virion - Hepatitis viruses 💬
1件: EGFR 💬 Erlotinib hydrochloride 💬 Erlotinib 2件: 94, 160 💬
306 Virion - Hepatitis viruses 💬
1件: EGFR 💬 Erlotinib 💬 Erlotinib 2件: 94, 160 💬
307 Wnt signaling pathway 💬
5件: PPP3C, PPP3C, PPP3C, PPP3R, PPP3R 💬 Pimecrolimus 💬 Pimecrolimus 1件: 160 💬
308 Yersinia infection 💬
1件: TNF 💬 Adalimumab 💬 Adalimumab 21件: 19, 37, 38, 40, 41, 46, 55, 56, 84, 96, 97, 107, 151, 160, 162, 164, 222, 226, 269, 270, 271 💬